Novartis Ag Adr (NVS)

Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - The Globe and Mail

Oct 04, 2025

Sep 30, 2025

Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight - GlobeNewswire Inc.

Sep 30, 2025

Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025

Sep 23, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Sep 23, 2025

Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025

Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025

Sep 13, 2025

UBS Sticks to Their Hold Rating for Novartis AG (NOVN) - The Globe and Mail

Sep 13, 2025

Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025

Sep 11, 2025

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail

Sep 11, 2025

Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025

Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025

Sep 09, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Sep 09, 2025

Sep 04, 2025

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm

Sep 04, 2025

Sep 04, 2025

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail

Sep 04, 2025

Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025

Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025

Aug 29, 2025

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm

Aug 29, 2025

Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025

Aug 19, 2025

Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail

Aug 19, 2025

Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025

Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025

Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025

Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025

Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025

Aug 01, 2025

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - The Globe and Mail

Aug 01, 2025

Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025